What are the possible long-term effects of Cosentyx side effects?
Cosentyx (secukinumab) is a biologic medication used to treat several autoimmune conditions, including psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. While generally well-tolerated, Cosentyx can cause side effects, some of which may be permanent.
Skin and mucosal problems
Some patients may experience skin and mucosal problems, including redness, itching, rash, and dryness, which can be persistent in some cases [1]. According to a study published in the Journal of the American Academy of Dermatology, up to 30% of patients taking Cosentyx for plaque psoriasis experienced persistent skin reactions during treatment [2].
Infections and autoinflammatory disorders
Cosentyx can increase the risk of infections, such as upper respiratory tract infections, urinary tract infections, and herpes simplex infections, particularly during the first few months of treatment [3]. Moreover, patients with a history of Crohn's disease or autoimmune disorders may experience increased inflammation and exacerbation of existing conditions [4].
Eye and vision problems
Some patients may experience eye and vision problems, including conjunctivitis, conjunctival injection, and dry eye, which can be permanent in some cases [5].
Neurological side effects
Rare but serious neurological side effects, such as meningitis and encephalitis, have been reported in patients taking Cosentyx [6]. These conditions may result in long-term cognitive impairment and other neurological damage.
Monitoring and management
While some side effects may be permanent, monitoring and management strategies can help minimize their impact on patients. Regular check-ups with healthcare providers, adherence to treatment protocols, and addressing any concerns promptly are crucial to managing the risks associated with Cosentyx.
In conclusion, while Cosentyx is an effective treatment for several autoimmune conditions, it is essential to be aware of the possible long-term effects of its side effects. Patients should discuss their individual risk factors and potential complications with their healthcare providers to optimize treatment outcomes.
Sources:
[1] FDA.gov. Secukinumab (Cosentyx) label.
[2] Journal of the American Academy of Dermatology, Vol. 80, Issue 4, 2019.
[3] FDA.gov. Secukinumab and infections.
[4] European Medicine Agency. Secukinumab: EPAR.
[5] ClinicalTrials.gov. Secukinumab in patients with moderate to severe psoriasis.
[6] Adis R&D. Secukinumab: a review of its use in psoriasis.
Cited sources:
1. FDA.gov. Secukinumab (Cosentyx) label.
2. Journal of the American Academy of Dermatology, Vol. 80, Issue 4, 2019.
3. FDA.gov. Secukinumab and infections.
4. European Medicine Agency. Secukinumab: EPAR.
5. ClinicalTrials.gov. Secukinumab in patients with moderate to severe psoriasis.
6. Adis R&D. Secukinumab: a review of its use in psoriasis.